Literature DB >> 33403881

Hormone replacement therapy - where are we now?

R D Langer1, H N Hodis2, R A Lobo3, M A Allison1.   

Abstract

Hormone replacement therapy (HRT) was the standard of care for menopause management until 2002, when perceptions changed following release of the initial results from the Women's Health Initiative (WHI) trial. Fears of breast cancer and heart attacks engendered by that report were not supported by the data, especially for recently menopausal women. Clinically, HRT is usually initiated near menopause. The WHI tested something different - the effects of HRT started a decade or more after menopause. As it turned out, age at starting HRT is critical in determining benefit/risk. HRT use plummeted following the WHI in 2002 and has remained low, prompting strong interest in alternative treatments. None provide the range of benefits across multiple organ systems offered by estrogen. Most have concerning adverse effects in their own right. HRT can provide effective relief for a wide range of health conditions, potentially avoiding the need for multiple treatments for separate problems. Unfortunately, among many women and clinicians, the perception of HRT benefit/risk is distorted, and its use avoided, leading to unnecessary distress. Following the WHI, many clinicians have not received adequate training to feel comfortable prescribing HRT. When initiated within 10 years of menopause, HRT reduces all-cause mortality and risks of coronary disease, osteoporosis, and dementias.

Entities:  

Keywords:  Hormone replacement therapy; breast cancer; coronary heart disease; genitourinary syndrome of menopause; menopause management; osteoporosis; vasomotor symptoms; women’s health

Year:  2021        PMID: 33403881     DOI: 10.1080/13697137.2020.1851183

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  5 in total

1.  Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.

Authors:  Patricia Loranca-Moreno; Juan Moises Ocampo-Godínez; Alan Rios-Espinosa; Magdalena Cruz-Luna; Carolina Garmendia-Gallardo; Merle Yasmin Hernández-Castañón; Verónica Yazmin Hernández-Hernández; Paula Mariana Sánchez-Tinoco; Alma Bajonero-Domínguez; Jael Adrián Vergara Lope-Núñez; Marco Antonio Álvarez-Pérez; José Luis González-Quiroz
Journal:  Arch Gynecol Obstet       Date:  2022-08-23       Impact factor: 2.493

2.  Why are women considering ovarian tissue cryopreservation to preserve reproductive and hormonal ovarian function? A qualitative study protocol.

Authors:  Hajra Khattak; Ioannis Gallos; Arri Coomarasamy; A E Topping
Journal:  BMJ Open       Date:  2022-04-13       Impact factor: 3.006

3.  Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis.

Authors:  Yu Deng; He Huang; Jiangcheng Shi; Hongyan Jin
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

4.  Status of female sexual dysfunction among postmenopausal women in Bangladesh.

Authors:  Mohammad Ashraful Amin; Nusrat-E Mozid; Sanjana Binte Ahmed; Shakila Sharmin; Imran Hossain Monju; Shirin Shahadat Jhumur; Wharesha Sarker; Koustuv Dalal; Mohammad Delwer Hossain Hawlader
Journal:  BMC Womens Health       Date:  2022-10-04       Impact factor: 2.742

5.  Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus.

Authors:  Soyeon Kang; Yong-Moon Park; Dong Jin Kwon; Youn-Jee Chung; Jeong Namkung; Kyungdo Han; Seung-Hyun Ko
Journal:  Diabetes Metab J       Date:  2022-01-24       Impact factor: 5.893

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.